Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN FRANCISCO , Oct. 22, 2014 ... fitness and health trackers for themselves and their kids, ... Mom 2014 Report: Health & Fitness Go Mobile for ... Mom® Insights Series. BabyCenter, the number 1 pregnancy and ... which found that 55 percent of moms surveyed say ...
(Date:10/22/2014)... -- A new report by Allied Market ... End user, Application and Geography) - Size, Share, Global ... Segmentation and Forecast, 2013 - 2020", considers commercial aspects ... trends tracked, it is anticipated that the market is ... registering a CAGR of 6.2% from 2014 to 2020. ...
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical ... Immunodeficiency Virus (HIV) infections, today announced its financial results and ... 30, 2011. GeoVax reported a net loss of ... 30, 2011, compared to $933,089 ($0.06 per share) for the ...
... Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies – today reported financial results for the three ... Recent and Upcoming Highlights ...
Cached Medicine Technology:GeoVax Labs, Inc. Announces Second Quarter Financial Results 2GeoVax Labs, Inc. Announces Second Quarter Financial Results 3GeoVax Labs, Inc. Announces Second Quarter Financial Results 4Spherix Announces Second Quarter Financial Results 2Spherix Announces Second Quarter Financial Results 3Spherix Announces Second Quarter Financial Results 4Spherix Announces Second Quarter Financial Results 5Spherix Announces Second Quarter Financial Results 6Spherix Announces Second Quarter Financial Results 7
(Date:10/25/2014)... York, New York (PRWEB) October 25, 2014 ... transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed ... litigation underway in U.S. District Court, Southern District ... for Summary Judgment on Punitive Damages in a ... plaintiffs. In a ruling issued on October 21st, ...
(Date:10/25/2014)... 2014 Limbkeepers® announced today that they ... with Ed Begley Jr, airing 1st QTR 2015 via ... this episode, Innovations will focus on Limbkeepers® non compression ... thinning skin on arms, hands, and legs from abrasion, ... versatile products, which help reduce injuries, allow for continued ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... sores -- herpes simplex -- might increase the risk of ... fact, being a carrier of certain antibodies to the virus ... "The identification of a treatable cause [herpes simplex] ... lead researcher Dr. Hugo Lovheim, an associate professor in the ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Researchers who discovered antibiotics ... are cause for concern. The use of ... for human consumption contribute to the development of ... background information from the study. Each year ... 2 million people and kill about 23,000, according ...
(Date:10/25/2014)... FRIDAY, Oct. 23, 2014 (HealthDay News) -- Current ... many younger postmenopausal women at risk for osteoporosis-related ... want to prevent fractures, we need tools that ... osteoporotic injuries so that we can target these ... Carolyn Crandall, professor of medicine in the division ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... 11 (HealthDay News) -- Naturally conceiving and giving birth to twins ... , The study found that among women who were born in ... to live longer than the mothers of singletons. University of ... Utah Population Database who were born between 1807 and 1899 and ...
... how well someone will control their emotions? To predict ... stress? To accept critical feedback stoically? ... University, finds clues in what psychologists call "hot" and "cold" ... can control their emotions, and one factor that predicts it ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... as erythropoietin alfa after a heart attack may experience new ... a new study finds. The drug, which stimulates red ... because certain studies suggested it might reduce the extent of ...
... and uninformed media portrayals of weight not only can ... approach issues of weight and health. The result, according ... (STOP) Obesity Alliance and the National Eating Disorders Association ... largely a matter of personal responsibility and that little ...
... Reporter , TUESDAY, May 10 (HealthDay News) -- Scientists have ... predict which breast cancer patients can benefit from specific types ... treatment, according to a study in the May 11 issue ... The findings are exciting but need to be replicated, ...
... , TUESDAY, May 10 (HealthDay News) -- Shortages of ... results of a new survey. The findings revealed that ... than 1,350 from the United States) are experiencing a shortage ... 98 percent of the respondents encountered a similar problem, the ...
Cached Medicine News:Health News:Moms Who Have Twins May Live Longer: Study 2Health News:When words get hot, mental multitaskers collect cool 2Health News:When words get hot, mental multitaskers collect cool 3Health News:Anemia Drug May Worsen Heart Attacks 2Health News:Anemia Drug May Worsen Heart Attacks 3Health News:Are words weighing down the development of policy for better health? 2Health News:Are words weighing down the development of policy for better health? 3Health News:Genetic Test Shows Promise in Guiding Breast Cancer Care 2Health News:Genetic Test Shows Promise in Guiding Breast Cancer Care 3Health News:Shortage of Anesthetics Reported 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: